Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 10/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 10/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8534162 | 0.80 | MTNR1A (0.56) | MTNR1AMTNR1BLMNA | |
| SCHEMBL8993024 | 0.75 | MTNR1A (0.60) | NPC1RAB9ASMN1; SMN2POLBBLM | |
| SCHEMBL5213132 | 0.74 | LOXL2 (0.71) | NPC1RAB9ASMN1; SMN2POLBBLM | |
| SCHEMBL28470846 | 0.74 | MTNR1A (0.55) | RAB9ASMN1; SMN2MTNR1AMTNR1BTP53 | |
| SCHEMBL4810894 | 0.74 | SMN1; SMN2 (0.57) | NPC1RAB9ASMN1; SMN2POLBBLM | |
| SCHEMBL27886412 | 0.73 | RAB9A (0.49) | NPC1RAB9ASMN1; SMN2POLBBLM | |
| SCHEMBL15761747 | 0.72 | CA1 (0.61) | NPC1RAB9ASMN1; SMN2POLBBLM | |
| Hydrochloric Acid SCHEMBL16506765 | 0.72 | HDAC1 (0.74) | NPC1RAB9ASMN1; SMN2POLBBLM | |
| SCHEMBL29879594 | 0.72 | CA1 (0.61) | NPC1RAB9ASMN1; SMN2POLBBLM | |
| Methyl 3-Methoxybenzoate SCHEMBL384913 | 0.70 | SMN1; SMN2 (0.73) | NPC1RAB9ASMN1; SMN2POLBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9707212-B2 | S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160045478-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC | 2016-02-18 | — | — | US | disclosed |
| EP-2533638-B1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | NIVALIS THERAPEUTICS INC (US) | 2016-02-10 | — | — | EP | disclosed |
| US-9187447-B2 | S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140275185-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8759548-B2 | S-nitrosoglutathione reductase inhibitors | N30 PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2533638-A1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120289555-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | N30 PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| WO-2011100433-A1 | NOVEL S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289555-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | GSR, GRHPR, POR | NPC1 2185/4885RAB9A 3507/4885SMN1; SMN2 4391/4885 |
| US-20160045478-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | GSR, GRHPR, POR | NPC1 2185/4885RAB9A 3507/4885SMN1; SMN2 4391/4885 |
| US-20140275185-A1 | Novel S-Nitrosoglutathione Reductase Inhibitors | GSR, GRHPR, POR | NPC1 2185/4885RAB9A 3507/4885SMN1; SMN2 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.